At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events

Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

Jun 30, 2014
Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012

May 14, 2014
Amicus Therapeutics to Present at UBS Global Healthcare Conference

View all »Events & Presentations

May 21, 2014 at 12:00 PM ET
UBS Global Healthcare Conference

May 5, 2014 at 5:00 PM ET
Amicus 1Q Results Conference Call and Webcast

Copyright © 2014 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy